Abstract
We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / therapeutic use*
-
Adult
-
BCG Vaccine / therapeutic use*
-
Brain / pathology
-
Cross-Over Studies
-
Female
-
Humans
-
Magnetic Resonance Imaging
-
Male
-
Multiple Sclerosis / diagnosis
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis / physiopathology
-
Recurrence
-
Treatment Outcome
Substances
-
Adjuvants, Immunologic
-
BCG Vaccine